Live
FierceBiotechAACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave risesFierceBiotechRacing toward first FDA nod for autoimmune CAR-T, Kyverna bolsters lead with full SPS datasetFierceBiotechRoche unpacks death imbalance, secondary endpoints in phase 3 multiple sclerosis trialsLonza NewsProject Hope Foundation receives $50K donation from Lonza Capsugel - Greenville JournalFierceBiotechPulnovo Medical scores $100M in finance round led by MedtronicIlluminaCSR News Feed | Explore the latest corporate social responsibility news from Illumina - IlluminaLonza NewsLonza Group AG stock (CH0013841017): Why biopharma contract manufacturing now matters more for U.S. - AD HOC NEWSDandong Aolong Radiative Instrument Group Co.,LtdWho Are the Top Competitors in the Bulk Petroleum and Chemical Storage Market Today - Weekly VoiceDandong Aolong Radiative Instrument Group Co.,LtdCompetitive Developments in the Industrial X-Ray Market: Strategies to Watch - Weekly VoiceIlluminaCSR News Feed | Explore the latest corporate social responsibility news from Illumina - Illumina10x Genomics BlogIs Atera’s New Spatial Biology Platform Altering The Investment Case For 10x Genomics (TXG)? - simplywall.stBrady CorporationMilwaukee’s Brady Corp Buying Honeywell Division - Seehafer News
Endpoints News Mar 5, 2026

Kura says its menin inhibitor is preferred treatment for some payers

Kura says its menin inhibitor is preferred treatment for some payers

Original
Body unavailable. Use the original source.